title: Stability and repeat regeneration potential of the engineered liver tissues under the kidney capsule in mice.
abstract: Liver tissue engineering using hepatocyte transplantation has been proposed as a therapeutic alternative to liver transplantation toward several liver diseases. We have previously reported that stable liver tissue with the potential for liver regeneration can be engineered at extrahepatic sites by transplanting mature hepatocytes into an extracellular matrix. The present study was aimed at assessing the liver tissue persistence after induced regeneration by hepatectomy and repeat regeneration potential induced by repeat hepatectomy. Mouse isolated hepatocytes mixed in EHS extracellular matrix gel were transplanted under both kidney capsules of isogenic mice. The hepatocyte survival persisted for over 25 weeks. In some of the mice, we confirmed that the grafted hepatocytes developed a thin layer of liver tissues under the kidney capsule, determined by specific characteristics of differentiated hepatocytes in cord structures between the capillaries. We then assessed the regenerative potential and persistence of the exogenous liver tissue. To induce liver regeneration, we performed a two-thirds hepatectomy at 70 days after hepatocyte transplantation. Three weeks after this procedure, the engineered liver tissues showed active regeneration, reaching serum marker protein levels of 261 +/- 42% of the prehepatectomy level. We found that the regenerated liver tissue was stably maintained for 100 days (length of the experiment). Repeat regeneration potential was established by performing a repeat hepatectomy (that had been two-thirds hepatectomized at day 70) 60 days after the initial hepatectomy. Again, the regenerated engineered liver tissues showed active regeneration as there was an approximately twofold increase in the serum marker protein levels. The present studies demonstrate that liver tissue, which was recognized as a part of the host naive liver in terms of the regeneration profile, could be engineered at a heterologous site that does not have access to the portal circulation.
authors.affiliation: Department of Surgery, Nara Medical University, Kashihara, Japan. kohashi@naramed-u.ac.jp
authors.forename: Kazuo
authors.initials: K
authors.lastname: Ohashi
authors.forename: Mark A
authors.initials: MA
authors.lastname: Kay
authors.forename: Takashi
authors.initials: T
authors.lastname: Yokoyama
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kuge
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Kanehiro
authors.forename: Michiyoshi
authors.initials: M
authors.lastname: Hisanaga
authors.forename: Saiho
authors.initials: S
authors.lastname: Ko
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Nakajima
mesh_terms: D000818:Animals; D006085:Graft Survival / Q000502:physiology; D006498:Hepatectomy; D022781:Hepatocytes / Q000166:cytology / Q000637:transplantation*; D006801:Humans; D008115:Liver Regeneration / Q000502:physiology*; D051379:Mice; D008822:Mice, Transgenic; D013370:Subrenal Capsule Assay / Q000379:methods*; D023822:Tissue Engineering; D000515:alpha 1-Antitrypsin / Q000096:biosynthesis / Q000235:genetics
chemical_list: D000515:alpha 1-Antitrypsin